Natera, Inc. (NASDAQ:NTRA) Q4 2021 Earnings Conference Call February 24, 2022 4:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - General Manager of Oncology & Transplant Conference Call Participants Tejas Savant - Morgan Stanley Puneet Souda - SVB Leerink Tycho Peterson - JPMorgan Catherine Schulte - Baird Max Masucci - Cowen & Company Mark Massaro - BTIG Dan Leonard - Wells Fargo Alex Nowak - Craig-Hallum Capital Group Kyle ...

8 natera × × × × × × × × × × × × × × × × × × Ⅹ Ｘ × × × × × × × × × × X X X X X X X × × Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ⅹ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Natera, Inc. Investor presentation Fourth Quarter 2021 Earnings Call Safe harbor statement This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our pro ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37478 NATERA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 01-0894487 State or Other Juris ...

8 natera Natera, Inc. Investor presentation JPM 2022 Ⅹ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ × × × × × × × × Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Safe harbor statement This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our proposed products and la ...

Financial Performance - Natera processed 407,000 tests in Q3 2021, a 55% increase compared to Q3 2020[5] - Total revenues for Q3 2021 reached $158 million, representing a 61% growth compared to Q3 2020[5] - Product revenues in Q3 2021 amounted to $151 million, a 62% increase compared to Q3 2020[5] - Natera is raising its revenue guidance from $600-$620 million to $615-$625 million, a $100 million increase from the start of the year[5] - Cash and investments stand at $1,023.9 million as of September 30, 2021, compared to $580.5 million as of June 30, 2021, representing a $443.4 million increase[30] Product Development and Validation - Prospera Kidney demonstrates improved sensitivity with the enhanced algorithm, showing overall sensitivity >99% and specificity 87.5%[17] - The Trifecta Study validates Prospera with Quantification, showing an area under the curve of 0.89 using molecular pathology as truth[18] - Prospera Heart transplant assessment test shows an area under the curve of 0.88 with Quantification[22] - Prospera lung test shows an area under the curve of 0.91 for acute rejection vs stable in the VALID study[23] Oncology - Signatera is selected for NRG Oncology's landmark CIRCULATE-US study[5] - Data validates Signatera velocity metric, showing a 43% 3-year overall survival for patients with fast tumor growth type (137% increase/mo) compared to 100% for slow growth type (27% increase/mo)[27]

Natera, Inc. (NASDAQ:NTRA) Q3 2021 Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - General Manager of Oncology & Transplant Conference Call Participants Tejas Savant - Morgan Stanley Tycho Peterson - JPMorgan Puneet Souda - SVB Leerink Catherine Schulte - Baird Alex Nowak - Craig-Hallum Capital Group Mark Massaro - BTIG Operator Welcome to Natera's 2021 Third Quarter Financial Resu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37478 NATERA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 01-0894487 (State or O ...

Natera, Inc. (NASDAQ:NTRA) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Conference Call Participants Tejas Savant - Morgan Stanley Tycho Peterson - JPMorgan Catherine Schulte - Baird Mark Massaro - BTIG Operator Welcome to Natera's 2021 Second Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management???s prepared remarks, we will ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37478 NATERA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 01-0894487 WASHINGTON, D.C. 20549 FORM 10-Q (State or Other ...

Financial Data and Key Metrics Changes - In Q1 2021, Natera processed 348,000 tests, representing an 18% growth over Q4 2020 and a 47% year-on-year growth [10] - Revenues reached $152 million, including a $28 million revenue recognition from QIAGEN, with a 36% year-on-year growth in product revenue when excluding this one-time event [11][21] - The company raised its revenue guidance for the year to a range of $550 million to $575 million, reflecting a significant increase of $50 million from previous estimates [12] Business Line Data and Key Metrics Changes - The women's health business continued to drive growth, with strong performance in oncology and organ health as well [10] - The launch of the Panorama AI algorithm improved cost efficiency and reduced no-call rates while maintaining sensitivity [12][23] - The Prospera launch for kidney transplant rejection testing is progressing well, with Medicare expanding coverage to other organ types [13][27] Market Data and Key Metrics Changes - The company is seeing increased penetration in the average risk market for NIPT, moving from approximately 20% to around 30% [66] - The demand for Signatera in oncology is growing, with significant interest from pharmaceutical partners and ongoing clinical trials [29][41] Company Strategy and Development Direction - Natera is focused on expanding its presence in the NIPT market and enhancing its product offerings through technological advancements [24][25] - The company aims to leverage its data from clinical studies to drive reimbursement approvals and market adoption [15][31] - Plans for early cancer detection are underway, with colorectal cancer as a primary focus before expanding to other cancer types [81] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory and the potential for improved average selling prices (ASPs) due to recent positive reimbursement decisions [44][68] - The company is cautious about seasonality effects, particularly in the women's health business, which typically sees a dip in Q2 [62] - Management highlighted the importance of ongoing investments in R&D and infrastructure to support growth [47] Other Important Information - The company is experiencing strong demand for its tests, with a significant increase in new customer acquisitions and competitive takeaways [66] - Natera is positioned to benefit from the recent Medicare coverage decisions, which could enhance its market opportunities [27] Q&A Session Summary Question: Insights on CIRCULATE-IDEA data and competitive positioning - Management believes they have a significant lead over competitors in the tumor-informed approach and are optimistic about the adoption of their tests [50][51] Question: Use case for multiple myeloma relative to competitors - The approach involves initial tumor analysis via bone marrow biopsy, followed by blood draws for ongoing monitoring, which is less invasive and more accessible [54] Question: Thoughts on early cancer screening opportunities - The company is making progress in early cancer screening and will provide updates in the future [59] Question: Volume trends and guidance for the year - Volume growth is strong, but seasonality in the women's health business is a factor in guidance [62] Question: Updates on NIPT reimbursement and microdeletions - Recent trends in ASPs are positive, and the company is working towards reimbursement for microdeletions [68][78]